1. A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment. Issue 5 (8th November 2013) Authors: Laille, Eric; Goel, Sanjay; Mita, Alain C.; Gabrail, Nashat Y.; Kelly, Kevin; Liu, Liangang; Songer, Stephen; Beach, Charles L. Journal: Pharmacotherapy Issue: Volume 34:Issue 5(2014) Page Start: 440 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher‐risk myelodysplastic syndromes. (28th January 2014) Authors: Seymour, John F.; Bennett, John M.; List, Alan F.; Mufti, Ghulam J.; Gore, Steven D.; Fenaux, Pierre; Santini, Valeria; Hetzer, Joel; Songer, Stephen; Skikne, Barry S.; Beach, Charles L. Journal: British journal of haematology Issue: Volume 165:Number 1(2014:Apr.) Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗